By Bhanvi Satija and Patrick Wingrove
(Reuters) -Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health’s decision to drop the company’s obesity drug Zepbound from the list of medicines it covers for reimbursement dragged shares down nearly 7%.
CVS said its pharmacy benefit management unit, which is the largest in the U.S., would drop Zepbound coverage from July 1, but keep reimbursing for rival GLP-1 weight-loss drug Wegovy after negotiating a more favorable price from Danish drugmaker Novo Nordisk.
Pharmacy benefit managers negotiate volume discounts and fees with drug manufacturers on behalf of employers and health plans, and create lists of medications that are covered by insurance. Prescriptions can be drastically reduced if these middlemen decide not to cover a drug.
The next two largest U.S. PBMs – UnitedHealth Group’s OptumRx and Cigna’s Express Scripts – did not immediately respond to queries about whether they were considering similar moves.
The success of Lilly’s popular weight-loss and diabetes treatments has made the Indianapolis-based drugmaker the world’s most valuable healthcare company, with a market value of more than $800 billion.
Two Lilly investors said CVS’ coverage decision will heat up the pricing competition between Novo and Lilly. But they were not immediately worried about impact to sales as patients and doctors seem to prefer Zepbound, they said.
“There’s always the risk of a price competition when your competitor Novo Nordisk is frankly not doing enough with its pipeline. So they may try to get a bit too aggressive on pricing just to maintain market share,” said Kevin Gade, portfolio manager at Bahl & Gaynor, which owns Lilly shares.
Lilly said lower prices for Zepbound trimmed revenue in the quarter, but that demand remained strong. Sales of the drug came in at $2.31 billion for the first quarter, slightly below analysts’ expectations of $2.33 billion, according to LSEG data.
Lilly in February cut the price for vials of Zepbound by $50 or more and expanded the range of doses it sold online to address competition from compounding pharmacies and Novo. It now offers the two lowest doses of Zepbound for $349 and $499 for a month’s supply.
OVERTAKING WEGOVY
Weekly U.S. prescriptions of Wegovy have plateaued since mid-February, according to IQVIA data provided by analysts. Zepbound recorded nearly 339,000 prescriptions for the week ending April 18, overtaking Novo’s obesity drug by more than 127,000.
Lilly said it had captured about 53.3% of the U.S. market share. IQVIA data suggested Lilly’s current share was closer to 62%.
